ArticleCancers2026
Mutations That Matter: Domain-Specific Mutational Hotspots in
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPatients with breast cancer (BC), and mostly triple-negative BC (TNBC), often exhibit poor prognosis due to variability in symptom manifestation and differential responses to treatment. TNBC among Indian women is the highest globally, contributing to increased mortality. A deeper understanding of the molecular factors influencing BC severity is essential for improving the therapeutic strategies.
objectiveThis study investigates differences in mutation patterns and positions in BRCA1 and its interacting partners, which contribute to variability in cancer manifestation and pathogenic burden.
methodsMutation analysis is performed using publicly available cancer genomics datasets. Independent cross-cohort comparisons were performed using the non-overlapping datasets to ensure multi-layered independent validation of the analysis. Additionally, multi-database validation was performed to confirm the consistency of pathogenic and likely pathogenic variants. The FDR-adjusted
resultsFunctional domains differ in their impact on the disease manifestation. Pathogenic mutations cluster in specific functional domains of BRCA1 and its interactors, with distinct patterns between BCGA and TCGA cohorts. These differences support the view that both mutation type and positional context shape pathogenic outcomes and highlight demographic variability in disease profiles.
conclusionThis study emphasizes that domain-specific mutation clustering is associated with increased pathogenic burden. Hence, consideration of protein-domain context may provide additional information beyond gene-level mutation to optimize stratification and treatment outcomes. The inclusion of the BCGA dataset provides novel population-specific insights, representing one of the first domain-level mutational analyses in an Indian breast cancer cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.